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Objective: To observe the therapeutic effects of electroacupuncture (EA) at Qiuxu (GB 40) for treatment of 
migraine so as to provide clinical evidence for compilation of the Acupoints’ Dictionary of the People’s 
Republic of China. Methods: 275 migraine patients admitted in 3 hospitals were randomly divided into a 
treatment group treated by EA at Qiuxu (GB 40), and a control group treated by EA at Tianshu (ST 25). The 
indexes of the migraine symptoms and the 5-HT level were observed in both the groups before and after 
treatment. Results: There was an significant difference in VAS score between the two groups of the 3 clinical 
centers (P<0.01). The therapeutic effects of a 4-week treatment were much better in the treatment group than 
that of the control group. The 3-month follow-up survey showed that the long-term effects were in favor of 
the treatment group of the first and third clinical centers, though no significant difference was found in the 
treatment group of the second clinical center as compared with the control group. The results from the 
6-month follow-up survey showed better effects in the treatment group of all the 3 clinical centers. 
Conclusion: EA at Qiuxu (GB 40) may show effect for migraine.    
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Migraine is a commonly and frequently encountered 
nervous headache caused by the nerve-vascular 
dysfunction, with repeated onsets on one side or both 
sides accompanied by nausea, vomiting and agitation.  
The authors have used electroacupuncture (EA) at 
Qiuxu (GB 40) of the Gallbladder Channel for 
treatment of migraine, with good therapeutic effects 
reported as follows. 
CLINICAL MATERIALS 
General data 
In this series, the 275 cases admitted were the 
outpatients from the Second affiliated Hospital of 
Hebei Medical University (the first clinical center), 
the TCM Hospital of Hebei Medical University (the 
second clinical center) and the Bethune International 
Peace Hospital (the third clinical center) including 
125 males and 150 females, aged 17–65 years (34 on 
the average), with the illness course ranging from 10 
days to 41 years (3.05 years on the average). 
Diagnostic criteria 
In the present study, the diagnostic criteria for 
migraine stipulated by the International Headache 
Society in 1988.1   
The migraine with no premonitory symptoms: 1) At 
least 5 onsets conform to the items 2–4; 2) each 
episode lasts 4–72 hours; 3) showing at least 2 of the 
following 4 conditions: a) unilateral headache, b) 
pulsative headache, c) moderate or severe headache 
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(daily activities are restricted or stopped), d) the 
headache is aggravated by going upstairs or the 
similar movements; 4) showing at least one of the 
following 2 symptoms: a) nausea and/or vomiting, b) 
aversion to light and sound; 5) conforming to at least 
one of the following 3 conditions: a) no symptomatic 
headache is indicated by the medical history, 
check-up and nervous system test, b) symptomatic 
headache indicated by the medical history, check-up 
and nervous system test can be ruled out by 
appropriate tests, c) there is no explicit relationship 
between the first onset of migraine and the time of 
symptomatic headache. 
The migraine with premonitory symptoms: 1) At least 
2 onsets conform to item 2; 2) showing at least 3 of 
the following features: a) one or more reversible 
premonitory symptoms are caused by local 
dysfunction of the cerebral cortex and/or brain stem, 
b) at least one premonitory symptom gradually 
occurs and lasts more than 4 min, or more than 2 
premonitory symptoms occur in succession, c) the 
premonitory symptoms last no more than 60 min, and 
if more than one premonitory symptoms occur, 
lasting time of migraine will increase accordingly, d) 
the headache occurs after the premonitory symptom 
with an interval less than 60 min (headache may 
occur before onset or at the same time with the 
premonitory symptom); 3) conforming to at least one 
of the following 3 conditions: a) no medical history, 
check-up and nervous system tests indicate 
symptomatic headache, b) the symptomatic headache 
indicated by the medical history, check-up and 
nervous system tests can be ruled out by appropriate 
tests, c) there is no explicit relationship between the 
first onset of migraine and the time of symptomatic 
headache.  
Criteria for admission
1) The patients conform to the above diagnostic 
criteria for migraine with or without the premonitory 
symptoms; 2) the patients are in the period of onset; 3) 
the age range is from 15–65 years; 4) the patients had 
at least one episode of migraine each month; 5) the 
patients are willing to take part in the research and 
sign a fact-known consent. 
Criteria for exclusion 
1) The patients with hypotension; 2) the patients have 
a history of epilepsy, apoplexy, organic diseases of 
the nervous system or the mental disorders; 3) Within 
one month before treatment, the patients have orally 
taken drugs or hormones for prevention and treatment 
of migraine, which may possibly influence the 
indexes to be observed; 4) the patients with severe 
primary diseases of the cardio-cerebral vessels, liver, 
kidney and the hematopoietic system; 5) pregnant 
women; 6) the patients with migraine caused by 
general disease, diseases of the five sense organs and 
the intracranial organic disorders. 
Random grouping
Eighty subjects were expected in each of the 3 
clinical centers. Considering a possible 15% dropout 
rate, 92 subjects admitted in each center were 
randomly and equally divided into 2 groups. One 
patient who took drugs for treating angina pectoris 
was rejected from the control group of the third 
clinical center. 
Comparison of the baselines between the two 
groups 
There was no siginificant difference in sex, age, the 
VAS index, illness course and the 5-HT level 
between the 2 groups of patients in the 3 clinical 
centers. Before treatment, no significant difference 
was found in the illness condition between the 2 
groups of the first and second clinical centers. 
However, the illness condition was milder in the 
control group of the third clinical center, showing a 
significant difference between the two groups.  
METHODS 
For the treatment group 
Bilateral Qiuxu (GB 40) were used for migraine on 
one side or both sides. The needles were vertically 
inserted 15–20 mm deep with the twirling, lifting and 
thrusting manipulations until obvious needling 
sensation was induced. Then, the needle handles were 
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connected to an electric stimulator, with the 
sparse-dense wave at frequency of 100 Hz. The 
intensity was gradually increased within the tolerance 
of the patient; and the needles were retained for 30 
min. 
For the control group 
The needle was vertically inserted into Tianshu (ST 
25) 20–30 mm deep with the twirling, lifting and 
thrusting manipulations until obvious needling 
sensation was induced. The electric stimulation and 
the needle retention were the same as done at Qiuxu 
(GB 40).   
The treatment was given once a day for 4 courses, 
with 5 sessions as one course and a 2-days interval in 
between. 
The indexes observed 
The index for immediate analgesic effect: The 
immediate analgesic effect refers to the analgesic 
effect immediately after the first treatment. The VAS 
scoring system was adopted to determine the grade of 
pain. Before treatment, the patients were taught to 
read the VAS scale. Put before the patient was a 
10-cm ruler scaled in 10 equal portions, with 0 at one 
end representing no pain and 10 at the other end 
representing the most severe pain. The patient 
estimated the painful degree and marked it at the 
corresponding position on the ruler. The score was  
zero for the mark at 0 position; the score was 1 for 
the mark at the position >0 but 2 cm; the score 2 for 
the position >2 but 4 cm; the score 3, >4 cm but 6 
cm; the score 4, >6 but 8 cm; and the score 5, >8 but 
10 cm. 
The indexes for long-term analgesic effect: The 
indexes included the painful degree, lasting time and 
frequency of the episodes, the accompanying 
symptoms and the plasma 5-HT level. The 
comprehensive scoring method suggested by SUN 
Zeng-hua et al. was used. 3 1) The painful degree: the 
score was 6 for the patients who had to lie in bed 
during the episode; the score was 4 for the patients 
with migraine onset affecting their work; the score 
was 2 for the headache that may not affect the work, 
and the score 0 for no headache at all. 2) The lasting 
time of episode: The score was 0 for no episode; the 
score was 1 for headache lasting from several min to 
2 hours; the score 2 for headache lasting 2–6 hours; 
the score 3 for headache lasting 6–24 hours; the score 
4 for headache lasting 24–72 hours; and the score 5 
for headache lasting over 72 hours. 3) The frequency 
of episodes: the score was 6 for 5 onsets per month; 
the score was 4 for 3–4 onsets per month; the score 2 
for 1–2 onsets per month; and the score zero for no 
onset at all. 4) The accompanying symptoms: the 
score was 3 for 3 or more accompanying symptoms, 
such as nausea, vomiting and aversion to light; the 
score was 2 for the headache accompanied by 2 
symptoms; the score was 1 for the headache 
accompanied by one symptom; and the score was 
zero for no accompanying symptoms at all. 5) The 
plasma 5-HT level: The score was 2 for the plasma 
5-HT level increased by more than 20%; and the 
score 1 for the plasma 5-HT level increased by less 
than 20%. 6) Grading of the headache: the integral 
score of 19 or more indicated severe headache; the 
integral score from 14 to <19 indicated moderate 
headache; the integral score from 8 to <14, the mild 
headache; and the integral score <8, the mildest 
headache.  
The follow-up survey 
No less than 85% of the subjects were followed up 4 
weeks, 3 months and 6 months after treatment. 
Statistical method 
SPSS11.5 statistic software was used to conduct the 
statistical analysis with Ȥ2 test, t test and Wilcoxon 
test. 
RESULTS 
Criteria for immediate analgesic effects 
The VAS scoring method was used to evaluate the 
immediate analgesic effects. Markedly relieved: the 
score in painful degree was reduced by 3 or more. 
Improved: the score in painful was reduced by 1 but 
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<3. Failed: the score in painful degree was reduced 
by <1. 
Criteria for analgesic effects in the follow-up 
survey 2 
Controlled: No episode after treatment, and no 
relapse in a period of 6 months. Markedly relieved: 
the integral score was reduced by more than 50%. 
Improved: the integral score was reduced by 20–50%. 
Failed: the integral score was reduced by less than 
20%. For patients with more than 5 episodes per 
month, if the frequency was decreased by more than 
75% after treatment, the score was reduced by 4; if 
the frequency was decreased by 50–75%, the score 
was reduced by 3; and for a frequency decreased by 
less than 50% but more than 20%, the score was 
reduced by 2. 
Comparison of the immediate analgesic effects 
between the two groups 
As shown in Table 1, there was no significant 
difference in immediate analgesic effects between the 
two groups of the first and second clinical centers 
(P>0.05). However, the effect in the treatment group 
was much better than that in the control group of the 
third clinical center (P<0.01).  
Comparison of the effects 4 weeks, 3 months and 6 
months after EA treatment between the two 
groups 
As shown in Table 2–4, there were significant 
differences in the effects 4 weeks after EA treatment 
between the 2 groups of the 3 clinical centers 
(P<0.05 or P<0.01) with better results shown in the 
treatment group. There was a significant difference in 
the effects 3 months after treatment between the 2 
groups of the first and third clinical centers (P<0.01) 
with better results shown in the treatment group. No 
significant difference was found in the effects 3 
months after treatment between the 2 groups of the 
second clinical center (P>0.05). There was a 
significant difference in the effects 6 months after 
treatment between the 2 groups of the 3 clinical 
centers (P<0.05 or P<0.01) with better results shown 
in the treatment group.  
Comparison of the 5-HT level 3 months after EA 
treatment between the two groups 
As shown in Table 5, there was a significant 
difference in the 5-HT level between the two groups 
of the 3 clinical centers (P<0.01), which was higher 
in the treatment group than that in the control group.
Table 1. Comparison of the immediate analgesic effects after EA treatment between the two groups (cases) 
Clinical center Group Markedly relieved Improved Failed Total 
Treatment group 5 21 20 46 
Control group 7 16 23 46 
The first 
Total 12 37 43 92 
Treatment group 0 37 9 46 
Control group 0 43 3 46 
The second 
Total 0 80 12 92 
Treatment group 2 32 12 46 
Control group 0 14 31 45 
The third 
Total 2 46 43 91 
Treatment group 7 90 41 138 
Control group 7 73 57 137 
All of the three centers
Total 14 163 98 275 
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Table 2. Comparison of curative effect 4 weeks after treatment between the 2 groups (cases) 
Clinical center Group Control Markedly relieved Improved Failed Total
Treatment group 24 7 2 10 43 
Control group 9 9 8 18 44 
The first 
Total 33 16 10 28 87 
Treatment group 14 14 9 8 45 
Control group 1 21 15 8 45 
The second 
Total 15 35 24 16 90 
Treatment group 0 0 26 20 46 
Control group 0 0 2 43 45 
The third 
Total 0 0 28 63 91 
Treatment group 38 21 37 38 134
Control group 10 30 25 69 134
All of the three centers
Total 48 51 62 107 268
Table 3. Comparison of curative effect 3 months after treatment between the 2 groups (cases) 
Clinical center Group Control Markedly relieved Improved Failed Total
Treatment group 31 4 3 5 43 
Control group 5 9 7 20 41 
The first 
Total 36 13 10 25 84 
Treatment group 12 18 7 8 45 
Control group 12 17 7 8 44 
The second 
Total 24 35 14 16 89 
Treatment group 0 2 28 16 46 
Control group 0 0 2 43 45 
The third 
Total 0 2 30 59 91 
Treatment group 43 24 38 29 134
Control group 17 26 16 71 130
All of the three centers
Total 60 50 54 100 264
Table 4. Comparison of curative effect 6 months after treatment between the 2 groups (cases) 
Clinical center Group Control Markedly relieved Improved Failed Total
Treatment group 29 6 1 7 43 
Control group 3 9 6 22 40 
The first 
Total 32 15 7 29 83 
Treatment group 35 3 2 4 44 
Control group 25 3 6 9 43 
The second 
Total 60 6 8 13 87 
Treatment group 0 1 30 12 43 
Control group 0 0 10 34 44 
The third 
Total 0 1 40 46 87 
Treatment group 64 10 33 23 130
Control group 28 12 22 65 127
All of the three centers
Total 92 22 55 88 257
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Table 5. Comparison of the plasma 5-HT level 3 months after treatment between the two groups (μg, x ±s). 
5-HT 
Clinical center 
Treatment group Control group 
The first 5.33±0.77 (43) * 4.06±0.65 (41) 
The second 5.81±0.82 (45) * 4.33±0.50 (44) 
The third 5.23±0.59 (46) * 4.34±0.44 (45) 
All of the three centers  5.46±0.77 (134) *  4.25±0.50 (130) 
Note: For intergroup comparison, *P<0.01; and in the brackets are the number of cases.  
DISCUSSION 
Migraine is a kind of vascular headache, manifested 
by repeated onsets on one for both sides of the head, 
often accompanied by nausea, vomiting and agitation, 
and mostly seen in women. Some of the patients may 
have family history. The pathogenesis may be 
possibly related with heredity, diet, endocrine, mental 
stress, hunger, deficient sleep, etc.   
Clinically, for acupuncture treatment of migraine, in 
addition to the local points used, the distal points are 
usually selected from the Foot-Shaoyng Channel 
such as Zulinqi (GB 41), Xiaxi (GB 43) and 
Zuqiaoyin (GB 44), and from the Hand-Shaoyang 
Channel such as Zhongzhu (TE 3) and Waiguan (TE 
5). 
However, for compilation of the Acupoints 
Dictionary of the People’s Republic of China, the 
indications should be introduced respectively for 
each of the points. So, in the present study, the 
therapeutic effects of EA at Qiuxu (GB 40) for 
migraine were evaluated based on the fact that in 
recent years, acupuncture at Qiuxu (GB 40) has been 
used for treating migraine though no such records can 
be found in the previous TCM medical books. 4-10  
Tianshu (ST 25) used in the control group were not 
selected from the same channel and not in the same 
nerve section with Qiuxu (GB 40). And no medical 
literatures have reported the use of Tianshu (ST 25) 
for treatment of migraine. 
The results from Table 1–4 showed that the 
therapeutic effects were in favor of the treatment 
group treated by EA at Qiuxu (GB 40) as compared 
with that of the control group treated by EA at 
Tianshu (ST 25). And as shown in Table 5, the 
plasma 5-HT level was significant higher in the 
treatment group than that of the control group 
(P<0.01). 
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